help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ross, D. S.
Right arrow Articles by Meskell, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ross, D. S.
Right arrow Articles by Meskell, M. J.

Journal of Clinical Endocrinology & Metabolism, Vol 69, 684-688, Copyright © 1989 by Endocrine Society

ARTICLES

Measurement of thyrotropin in clinical and subclinical hyperthyroidism using a new chemiluminescent assay

DS Ross, LJ Ardisson and MJ Meskell
Department of Medicine, Massachusetts General Hospital, Boston 02114.

A new commercially available chemiluminescent TSH assay demonstrates an 8- to 10-fold increase in sensitivity over a sensitive immunoradiometric assay, allowing increased ability to distinguish partial from more complete thyrotroph suppression. Sera were analyzed from 145 patients who had TSH concentrations below 0.08 mU/L in the immunoradiometric assay. Most patients with overt hyperthyroidism had undetectable TSH concentrations in the chemiluminescent assay. Three groups of patients were identified, in which a large subgroup had undetectable values in the immunoradiometric assay and detectable values in the chemiluminescent assay (12 of 17 patients under treatment for hyperthyroidism who had recently normalized their serum thyroid hormone levels, 33 of 68 patients taking L-T4, and 4 of 8 patients with endogenous subclinical hyperthyroidism). In addition, several patients with undetectable basal and detectable TRH-stimulated TSH values in the immunoradiometric assay had detectable basal TSH values in the chemiluminescent assay. The utility of first generation TSH immunometric assays was their ability to distinguish hyperthyroidism from euthyroidism. The clinical utility of increasingly sensitive TSH assays will be to distinguish degrees of thyrotroph suppression in subclinical hyperthyroidism.


This article has been cited by other articles:


Home page
 Endocr. Rev.Home page
B. Biondi and D. S. Cooper
The Clinical Significance of Subclinical Thyroid Dysfunction
Endocr. Rev., February 1, 2008; 29(1): 76 - 131.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Ito, J. Takamatsu, S. Yoshida, Y. Murakami, S. Sakane, K. Kuma, and N. Ohsawa
Incomplete Thyrotroph Suppression Determined by Third Generation Thyrotropin Assay in Subacute Thyroiditis Compared to Silent Thyroiditis or Hyperthyroid Graves' Disease
J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 616 - 619.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1989 by The Endocrine Society